| abstract |
A solid pharmaceutical composition of solifenacin or a salt thereof, wherein the preparation is stable and inhibited against degradation over time by clinical application. In a pharmaceutical composition containing solifenacin or a salt thereof, it was shown that the compound in amorphous form was the cause of the major degradation of the drug over time. The composition of a solid pharmaceutical composition of solifenacin or a salt thereof contains solifenacin or a salt thereof, both in crystalline form, and the content of the compound in amorphous form is within a range which does not affect the stability of the product. Furthermore, there is provided a process for preparing the composition and a medical composition for solid pharmaceutical compositions containing solifenacin and a compound which inhibits the formation of amorphous material. |